1
|
Brenner AJ, Lengfelder L, Quach DK, Cavazos DA, Ramirez RJ, Gruslova A, Kist K, Lathrup K, Kaklamani V, Beeram M, deGraffenried LA. Abstract P1-09-16: Randomized study of COX2 inhibition on systemic inflammation in obese and non-obese subjects. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Obesity is associated with poor breast cancer outcomes in postmenopausal women. Our prior retrospective studies have shown that use of nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with reduced recurrence in obese breast cancer patients and a doubling of time to recurrence. Because it was recently determined that CD163+ M2 macrophages were clinically associated with fast proliferation, poor differentiation, estrogen receptor negativity and histological duct type in human primary breast tumors, the mechanism proposed was a decrease in prostaglandin E2 (PGE2) and aromatase locally in the breast with a concomitant decrease in circulating M2-activated tumor associated macrophages (TAMs).
Methods: Postmenopausal women of varying body habitus were recruited at the CTRC in San Antonio and underwent randomized assignment to 1 of 3 arms: Aspirin (ASA) at 81mg daily, 1500mg of docosahexaenoic acid (DHA) and 2500mg eicosapentaenoic acid (EPA) given daily, or combined ASA and DHA/EPA. Sera were collected prior to and following 28 days of exposure, and cytokines including prostaglandin E2 were assessed via enzyme linked immunosorbent assay (ELISA). 28 circulating cytokines/chemokines were assessed by Luminex array using Millipore Milliplex MAP to look for associations between cytokine array profiles, PGE2 production and macrophage activation. Circulating class M-1 activated and M-2 activated macrophages were enumerated by flow cytometry to assess how PGE2 modulation influences macrophage phenotype and function. Investigators were blinded to randomization until analysis was complete.
Results: A total of 122 patients were randomized with 2 drop outs and 115 completing the 28 days of intervention as planned. The median BMI was 31.4, with 12.8% normal (BMI <25.0), 27.3% overweight (25.0-29.9), and 59.9% obese (>29.9). Patients had a median age of 63 (47-76), 91% white, and 46.0 % Hispanic. A positive correlation was observed between BMI and baseline PGE2 levels. The most consistent impact on PGE2 was observed with ASA with 81% obtaining a decrease from baseline (median change -28%); by comparison 55.1% (-1%) and 65.6% (-22%) of subjects showed decrease in the DHA/EPA and combined groups respectively. As of today, full cytokine profiling was performed on a subset of 38 patients and revealed a positive correlation with change in PGE2 and cytokines: EGF, Eotaxin, GM-CSF, IL1Ra, IL5, IL8, MIP1b, and TNFa.
Conclusion: Aspirin alone most consistently impacted patient circulating PGE2 levels, and will be used in planned studies as an adjunct to adjuvant endocrine therapy in obese hormone receptor positive post-menopausal patients. Full cytokine and macrophage activation status will be reported.
Citation Format: Brenner AJ, Lengfelder L, Quach DK, Cavazos DA, Ramirez RJ, Gruslova A, Kist K, Lathrup K, Kaklamani V, Beeram M, deGraffenried LA. Randomized study of COX2 inhibition on systemic inflammation in obese and non-obese subjects [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-16.
Collapse
Affiliation(s)
- AJ Brenner
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - L Lengfelder
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - DK Quach
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - DA Cavazos
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - RJ Ramirez
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - A Gruslova
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - K Kist
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - K Lathrup
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - V Kaklamani
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - M Beeram
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| | - LA deGraffenried
- CTRC at UT Health Science Center San Antonio, San Antonio, TX; UT Austin, Austin, TX; START Center for Cancer Care, San Antonio, TX
| |
Collapse
|
2
|
Lengfelder L, Brenner A, Bowers L, Apte S, Galván G, Kist K, deGraffenried L. Abstract P3-14-12: Phase 0 study evaluating COX2 inhibition on circulating PGE2 levels from obese subjects. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-14-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Obesity is associated with poor breast cancer outcomes in postmenopausal women in response to aromatase inhibitor therapy. Our prior studies have shown an association between reduced recurrence rate and use of cyclooxygenase-2 (COX-2) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) in obese breast cancer patients. The mechanism proposed was a decrease in prostaglandin E2 (PGE2) and reduced activation of the aromatase promote locally in the breast.
Methods: Postmenopausal women of varying body habitus were recruited at the CTRC in San Antonio and underwent randomized assignment to 1 of 3 arms: ASA 81mg daily, 1500mg of docosahexaenoic acid (DHA) and 2500mg eicosapentaenoic acid (EPA) given daily, or combined ASA and DHA/EPA. Sera were collected prior to and following 28 days of exposure, and cytokines including prostaglandin E2 were assessed via enzyme-linked immunosorbant assay (ELISA). Conditioned media was generated by exposing macrophages to patient sera in order to see if the patient sera induced PGE2 concentration in vitro.
Results: Thirty of the planned 120 subjects have completed assessment. No toxicity has been noted. In 71% of the patients, serum PGE2 levels decreased, but only 60% demonstrated concurrent decrease in serum PGE2 levels as well as macrophage PGE2 production, while almost all (88%) of the patients whose serum did not demonstrate a decrease in PGE2 levels also demonstrated no decrease in induced levels.
Conclusion: NSAIDs appear to effectively decrease circulating levels of PGE2 in most obese women. However, one third of the subjects did not demonstrate concurrent suppression of induced PGE2 from macrophages. These data suggest that circulating levels of PGE2 may not be reflective of local tumor microenvironment levels, and other pro-inflammatory circulating factors may be responsible for regulating local inflammatory responses. Final analysis will be completed and presented at the SABCS meeting.
Citation Format: Lengfelder L, Brenner A, Bowers L, Apte S, Galván G, Kist K, deGraffenried L. Phase 0 study evaluating COX2 inhibition on circulating PGE2 levels from obese subjects. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-14-12.
Collapse
Affiliation(s)
- L Lengfelder
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| | - A Brenner
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| | - L Bowers
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| | - S Apte
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| | - G Galván
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| | - K Kist
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| | - L deGraffenried
- The University of Texas at Austin, Austin, TX; UTHSCSA, San Antonio, TX
| |
Collapse
|